Trovagene's drug candidate PCM-075 received FDA orphan status as a treatment for acute myeloid leukemia. The oral drug inhibits the serine/threonine Polo-like Kinase 1 enzyme, which is over-expressed in a number of blood and other cancers.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.